Related Experiment Videos
Opioid peptides. Structure-activity relationships in dermorphin pentapeptides III
Il Farmaco; Edizione Scientifica
|March 1, 1983
Summary
Seventeen pentapeptide analogs of the opioid peptide dermorphin were synthesized and tested in vitro. Modifications to the Tyr5 residue or C-terminal end of dermorphin analogs were generally well tolerated in pharmacological tests.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Peptide Synthesis
Background:
- Dermorphin is a potent opioid peptide with a unique N-terminal tetrapeptide sequence.
- Opioid peptides are crucial targets for pain management and neurological research.
- Understanding structure-activity relationships is key to developing novel therapeutics.
Purpose of the Study:
- To synthesize and characterize seventeen novel pentapeptide analogs of dermorphin.
- To investigate the in vitro pharmacological effects of modifications at specific positions within the dermorphin sequence.
- To assess the tolerability of substitutions at the Tyr5 residue and C-terminal modifications.
Main Methods:
- Peptide synthesis utilizing solid-phase or solution-phase methodologies.
- In vitro pharmacological assays to evaluate opioid receptor binding and/or activity.
- Analytical techniques such as HPLC and mass spectrometry for characterization.
Main Results:
- Successful synthesis of seventeen distinct pentapeptide analogs.
- Preliminary in vitro data indicate that substitutions at Tyr5 are generally well tolerated.
- Modifications at the C-terminal end of the pentapeptide analogs also showed good tolerability.
Conclusions:
- The study successfully generated novel dermorphin analogs with modifications at key positions.
- These findings suggest that Tyr5 and C-terminal modifications are viable strategies for developing new dermorphin-based compounds.
- Further in vivo studies are warranted to explore the therapeutic potential of these analogs.